Coeptis Therapeutics Holdings 2025 10-K: $1.36M Revenue, Operating Loss $14.23M
I'm LongbridgeAI, I can summarize articles.Coeptis Therapeutics Holdings reported $1.36 million in revenue for 2025, primarily from NexGenAI services, but incurred an operating loss of $14.23 million. This marks the company's first significant revenue from its technology pivot while its biotech programs remain in development. Management plans to increase R&D and administrative spending to support the GEAR and SNAP-CAR platforms. The company also secured exclusive rights to the GEAR platform and advanced several therapeutic programs, despite terminating a contract with Deverra as part of organizational changes.
Coeptis Therapeutics Holdings reported $1.363045 million in revenue for the year ended 2025, driven by NexGenAI lead-generation and webinar services, while recording operating expenses that produced an operating loss of $14.225918 million; earnings per share (EPS) and net income figures were not disclosed in the extracted sections. The results mark the company's first meaningful commercial revenue from its technology services pivot as the biotechnology programs remain development-stage. Management signaled increased R&D and general and administrative spending ahead to support advancement of its GEAR and SNAP-CAR platforms.
Financial Highlights
- Revenue (Sales): $1.363045 million — primarily from NexGenAI lead-generation and webinar services in 2025.
- Operating Income: $(14.225918) million — operating expenses totaled $14.225918 million for the year ended 2025.
- Net Income: Not provided in the extracted sections.
- Net Income Per Share (EPS): Not provided in the extracted sections.
Business Highlights
- Revenue Growth & Business Shift: Generated $1.36 million in 2025 from NexGenAI lead-generation and webinars, representing the first meaningful commercial revenue as the company pivots toward technology services while maintaining development-focused biotech activities.
- Product Focus & Licensing: Secured exclusive rights to the GEAR™ platform in March 2025 and holds a license from Deverra (August 2023) to expand cell therapy offerings.
- Program Advances: Advanced CD38-GEAR-NK and CD38-Diagnostic programs; completed asset purchases and IND-related activities supporting therapeutic development.
- Contract and Asset Changes: Terminated the SSA with Deverra in December 2024 as part of organizational and programmatic adjustments.
- R&D and Infrastructure Outlook: Anticipates increased research and development and general and administrative expenditures to support GEAR and SNAP-CAR development and to scale operations.
Original SEC Filing: Coeptis Therapeutics Holdings, Inc. [ COEP ] - 10-K - Mar. 19, 2026